Search
Alzamend Neuro Inc
ALZNAdd to Watchlist
1.940USD
0.0000.00%
Market hours 09/23, 15:18（ET）
9.29MMarket Cap
LossP/E TTM
About Alzamend Neuro Inc Company
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.
Alzamend Neuro Inc Profile
Ticker SymbolALZN
Company nameAlzamend Neuro Inc
IPO dateJun 15, 2021
CEOJackman (Stephan)
Number of employees4
Security typeOrdinary Share
Fiscal year-endJun 15
Address480 Peachtree Road Ne, Second Floor
CityATLANTA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code30326
Phone18447226333
Websitehttps://alzamend.com/
Ticker SymbolALZN
IPO dateJun 15, 2021
CEOJackman (Stephan)
Company Executives of Alzamend Neuro Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David J. Katzoff
Mr. David J. Katzoff
Chief Financial Officer
Chief Financial Officer
615.00
--
Mr. David J. Katzoff
Mr. David J. Katzoff
Chief Financial Officer
Chief Financial Officer
615.00
--
Dr. Andrew H. Woo, M.D., Ph.D.
Dr. Andrew H. Woo, M.D., Ph.D.
Independent Director
Independent Director
74.00
--
Mr. Jeffrey Oram
Mr. Jeffrey Oram
Independent Director
Independent Director
74.00
--
Dr. Andrew H. Woo, M.D., Ph.D.
Dr. Andrew H. Woo, M.D., Ph.D.
Independent Director
Independent Director
74.00
--
Mr. Jeffrey Oram
Mr. Jeffrey Oram
Independent Director
Independent Director
74.00
--
Mr. Stephan Jackman
Mr. Stephan Jackman
Chief Executive Officer, Director
Chief Executive Officer, Director
50.00
+34.00%
Mr. Stephan Jackman
Mr. Stephan Jackman
Chief Executive Officer, Director
Chief Executive Officer, Director
50.00
+34.00%
Mr. Mark Garland Gustafson
Mr. Mark Garland Gustafson
Independent Director
Independent Director
44.00
--
Mr. Mark Garland Gustafson
Mr. Mark Garland Gustafson
Independent Director
Independent Director
44.00
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David J. Katzoff
Mr. David J. Katzoff
Chief Financial Officer
Chief Financial Officer
615.00
--
Mr. David J. Katzoff
Mr. David J. Katzoff
Chief Financial Officer
Chief Financial Officer
615.00
--
Dr. Andrew H. Woo, M.D., Ph.D.
Dr. Andrew H. Woo, M.D., Ph.D.
Independent Director
Independent Director
74.00
--
Mr. Jeffrey Oram
Mr. Jeffrey Oram
Independent Director
Independent Director
74.00
--
Dr. Andrew H. Woo, M.D., Ph.D.
Dr. Andrew H. Woo, M.D., Ph.D.
Independent Director
Independent Director
74.00
--
Mr. Jeffrey Oram
Mr. Jeffrey Oram
Independent Director
Independent Director
74.00
--
FAQs
Who are the top five shareholders of Alzamend Neuro Inc?
The top five shareholders of Alzamend Neuro Inc are: Mr. David J. Katzoff
How many institutions hold shares of Alzamend Neuro Inc (ALZN)?
As of 2026Q1, 24 institutions hold shares of Alzamend Neuro Inc, with a combined market value of approximately 225.59K, accounting for 5.93% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 45969.00.